|Table of Contents|

Research progress of CRISPR/Cas9 technology in endometrial cancer treatment

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 02
Page:
321-326
Research Field:
Publishing date:

Info

Title:
Research progress of CRISPR/Cas9 technology in endometrial cancer treatment
Author(s):
NIU Yimo; WANG Yuning; ZHANG Yi
Department of Gynecology,the First Affiliated Hospital of China Medical University,Liaoning Shenyang 110001,China.
Keywords:
CRISPR/Cas9; gene editing; endometrial cancer; treatment
PACS:
R737.33
DOI:
10.3969/j.issn.1672-4992.2025.02.024
Abstract:
Endometrial cancer(EC) is the second most common gynecologic malignancy worldwide.For patients with advanced or recurrent endometrial cancer,the traditional surgery and radiotherapy or chemotherapy treatments have been marginally effective,posing a major challenge that needs urgent resolution.By precisely modifying genome sequences to induce insertions,deletions,or base substitutions in the genome,CRISPR/Cas9 gene editing technology has been widely applied in exploring the mechanisms of cancer development,potential therapeutic targets,and the construction of cancer models.It also provides new potential pathogenic targets and treatment options for clinical research on endometrial cancer.This article mainly reviews the CRISPR/Cas9 technology and its research progress of endometrial cancer in recent years,aiming to lay a foundation for research in this field and provide references for the clinical treatment of endometrial cancer.

References:

[1] GARNEAU JE,DUPUIS M,VILLION M,et al.The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA ［J］.Nature,2010,468(7320):67-71.
[2] ISHINO Y,SHINAGAWA H,MAKINO K,et al.Nucleotide sequence of the iap gene,responsible for alkaline phosphatase isozyme conversion in Escherichia coli,and identification of the gene product ［J］.Journal of Bacteriology,1987,169(12):5429-5433.
[3] SHALEM O,SANJANA NE,HARTENIAN E,et al.Genome-scale CRISPR-Cas9 knockout screening in human cells ［J］.Science,2013,343(6166):84-87.
[4] CONG L,RAN FA,COX D,et al.Multiplex genome engineering using CRISPR/Cas systems［J］.Science,2013,339(6121):819-823.
[5] WONG C.UK first to approve CRISPR treatment for diseases:what you need to know［J］.Nature,2023,623(7988):676-677.
[6] SIEGEL RL,MILLER KD,WAGLE NS,et al.Cancer statistics,2023［J］.CA:A Cancer Journal for Clinicians,2023,73(1):17-48.
[7] 夏玲芳,朱俊,吴小华.2023年ESMO妇科肿瘤治疗最新进展及展望［J］.中国癌症杂志,2023,33(11):969-980. XIA LF,ZHU J,WU XH.The latest progress and prospect of gynecological tumor treatment at 2023 ESMO［J］.China Oncology,2023,33(11):969-980.
[8] GORDHANDAS S,ZAMMARRELLI WA,RIOS-DORIA EV,et al.Current evidence-based systemic therapy for advanced and recurrent endometrial cancer ［J］.Journal of the National Comprehensive Cancer Network,2023,21(2):217-226.
[9] DOUDNA JA,CHARPENTIER E.The new frontier of genome engineering with CRISPR-Cas9［J］.Science,2014,346(6213):1258096.
[10] JINEK M,CHYLINSKI K,FONFARA I,et al.A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity ［J］.Science,2012,337(6096):816-821.
[11] MALI P,YANG L,ESVELT KM,et al.RNA-guided human genome engineering via Cas9［J］.Science,2013,339(6121):823-826.
[12] 方锐,畅飞,孙照霖,等.CRISPR/Cas9介导的基因组定点编辑技术［J］.生物化学与生物物理进展,2013,40(8):691-702. FANG R,CHANG F,SUN ZL,et al.New method of genome editing derived from CRISPR/Cas9［J］.Progress in Biochemistry and Biophysics,2013,40(8):691-702.
[13] HE C,HAN S,CHANG Y,et al.CRISPR screen in cancer:status quo and future perspectives［J］.American Journal of Cancer Research,2021,11(4):1031-1050.
[14] LI J,XU R,QIN R,et al.Genome editing mediated by SpCas9 variants with broad non-canonical protospacer-adjacent motif compatibility in plants［J］.Molecular Plant,2021,14(2):352-360.
[15] JIANG F,DOUDNA JA.CRISPR-Cas9 Structures and Mechanisms［J］.Annual Review of Biophysics,2017,46(1):505-529.
[16] ROTH TL,LI PJ,BLAESCHKE F,et al.Pooled knockin targeting for genome engineering of cellular immunotherapies［J］.Cell,2020,181(3):728-744.e21.
[17] ALAGOZ M,KHERAD N.Advance genome editing technologies in the treatment of human diseases:CRISPR therapy (Review) ［J］.International Journal of Molecular Medicine,2020,46(2):521-534.
[18] LI M,CHEN F,YANG Q,et al.Biomaterial-based CRISPR/Cas9 delivery systems for tumor treatment［J］.Biomaterials Research,2024,28(23):23.
[19] YIN H,XUE W,ANDERSON DG.CRISPR-Cas:a tool for cancer research and therapeutics［J］.Nature Reviews Clinical Oncology,2019,16(5):281-295.
[20] UNGRICHT R,GUIBBAL L,LASBENNES MC,et al.Genome-wide screening in human kidney organoids identifies developmental and disease-related aspects of nephrogenesis［J］.Cell Stem Cell,2021,29(1):160-175.
[21] LU Y,XUE J,DENG T,et al.Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer［J］.Nature Medicine,2020,26(5):732-740.
[22] FRANGOUL H,ALTSHULER D,CAPPELLINI MD,et al.CRISPR-Cas9 gene editing for sickle cell disease and β-Thalassemia［J］.New England Journal of Medicine,2021,384(3):252-260.
[23] 王琳琳,李红玲.CRISPR/Cas9基因编辑技术在精准肿瘤学研究中的应用［J］.中国肿瘤生物治疗杂志,2024,31(05):519-527. WANG LL,LI HL.Application of CRISPR/Cas9 gene editing technology in the research of precision oncology［J］.Chin J Cancer Biother,2024,31(05):519-527.
[24] CHEN B,DENG Y,REN X,et al.CRISPR/Cas9 screening:unraveling cancer immunotherapy's ' Rosetta Stone ' ［J］.Trends in Molecular Medicine,2024,30(8):736-749.
[25] CHEN C,WANG Z,QIN Y.CRISPR/Cas9 system:recent applications in immuno-oncology and cancer immunotherapy［J］.Experimental Hematology & Amp Oncology,2023,12(1):95.
[26] QIAO Z,JIANG Y,WANG L,et al.Mutations in KIAA1109,CACNA1C,BSN,AKAP13,CELSR2,and HELZ2 are associated with the prognosis in endometrial cancer ［J］.Frontiers in Genetics,2019,10:909.
[27] MATIAS-GUIU X,PRAT J.Molecular pathology of endometrial carcinoma［J］.Histopathology,2012,62(1):111-123.
[28] NAVARIDAS R,VIDAL-SABANS M,RUIZ-MITJANA A,et al.In vivo intra-uterine delivery of TAT-Fused cre recombinase and CRISPR/Cas9 editing system in mice unveil histopathology of Pten/p53-deficient endometrial cancers［J］.Advanced Science(Weinheim,Baden-Wurttemberg,Germany),2023,10(32):e2303134.
[29] LYU C,ZHANG Y,ZHOU X,et al.ARID1A gene silencing reduces the sensitivity of ovarian clear cell carcinoma to cisplatin［J］.Experimental and Therapeutic Medicine,2016,12(6):4067-4071.
[30] ANDROUTSOPOULOS G,STYLIARA I,ZAROGIANNI E,et al.The ErbB signaling network and its potential role in endometrial cancer［J］.Epigenomes,2023,7(4):24.
[31] WANG H,TANG Z,LI T,et al.CRISPR/Cas9-mediated gene knockout of ARID1A promotes primary progesterone resistance by downregulating progesterone receptor B in endometrial cancer cells［J］.Oncology Research,2019,27(9):1051-1060.
[32] XIA C,DONG X,LI H,et al.Cancer statistics in China and United States,2022:profiles,trends,and determinants［J］.Chinese Medical Journal,2022,135(5):584-590.
[33] SIEGEL RL,MILLER KD,FUCHS HE,et al.Cancer statistics,2021 ［J］.CA:A Cancer Journal for Clinicians,2021,71(1):7-33.
[34] LIU Z,SHI M,REN Y,et al.Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy［J］.Molecular Cancer,2023,22(1):1-19.
[35] WANG TS,GAO F,QI QR,et al.Dysregulated LIF-STAT3 pathway is responsible for impaired embryo implantation in a streptozotocin-induced diabetic mouse model ［J］.Biology Open,2015,4(7):893-902.
[36] CHEN CL,HSIEH FC,LIEBLEIN JC,et al.Stat3 activation in human endometrial and cervical cancers［J］.British Journal of Cancer,2007,96(4):591-599.
[37] YU H,YUE X,ZHAO Y,et al.LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers ［J］.Nature Communications,2014,5(1):5218.
[38] TANG W,RAMASAMY K,PILLAI SM A,et al.LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer［J］.Cell Death Discovery,2021,7(1):216.
[39] SPENCER N,RODRIGUEZ SANCHEZ AL,GOPALAM R,et al.The LIFR inhibitor EC359 effectively targets type II endometrial cancer by blocking LIF/LIFR oncogenic signaling ［J］.International Journal of Molecular Sciences,2023,24(24):17426.
[40] LI Y,ZHOU W,MENG X,et al.Utilizing an endogenous progesterone receptor reporter gene for drug screening and mechanistic study in endometrial cancer［J］.Cancers,2022,14(19):4883.
[41] WEINBERG SE,CHANDEL NS.Targeting mitochondria metabolism for cancer therapy［J］.Nature Chemical Biology,2014,11(1):9-15.
[42] TAKAHASHI N,HATAKEYAMA K,NAGASHIMA T,et al.Activation of oxidative phosphorylation in TP53-inactive endometrial carcinomas with a poor prognosis［J］.International Journal of Gynecologic Cancer,2021,31(12):1557-1563.
[43] LARSSON NG,WANG J,WILHELMSSON H,et al.Mitochondrial transcription factor A is necessary for mtDNA maintance and embryogenesis in mice ［J］.Nature Genetics,1998,18(3):231-236.
[44] LI SP,OU L,ZHANG Y,et al.A first-in-class POLRMT specific inhibitor IMT1 suppresses endometrial carcinoma cell growth［J］.Cell Death & Disease,2023,14(2):152.
[45] CAI J,WU D,JIN Y,et al.Effect of CMB carrying PTX and CRISPR/Cas9 on endometrial cancer naked mouse model［J］.Journal of Healthcare Engineering,2022,2022:7119195.
[46] NAVARIDAS R,VIDAL-SABANS M,RUIZ-MITJANA A,et al.Transient and DNA-free in vivo CRISPR/Cas9 genome editing for flexible modeling of endometrial carcinogenesis［J］.Cancer Communications(London,England),2023,43(5):620-624.
[47] GEURTS MH,GANDHI S,BORETTO MG,et al.One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids［J］.Nature Communications,2023,14(1):4998.
[48] BORETTO M,COX B,NOBEN M,et al.Development of organoids from mouse and human endometrium showing endometrial epithelium physiology and long-term expandability［J］.Development,2017,144(10):1775-1786.

Memo

Memo:
辽宁省应用基础研究计划(编号：2022JH2/101300039）;2022年沈阳市科技计划（编号：22-321-33-08）
Last Update: 1900-01-01